| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
|
N Engl J Med
|
2005
|
8.77
|
|
2
|
Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
|
Chest
|
2012
|
5.57
|
|
3
|
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
|
JAMA
|
2002
|
5.26
|
|
4
|
VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
|
Chest
|
2012
|
4.50
|
|
5
|
Global epidemiology of hepatitis B virus.
|
J Clin Gastroenterol
|
2004
|
4.48
|
|
6
|
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.
|
Blood
|
2008
|
4.02
|
|
7
|
Warfarin pharmacogenetics.
|
Pharmacotherapy
|
2008
|
2.50
|
|
8
|
Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis.
|
Ann Intern Med
|
2002
|
2.43
|
|
9
|
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.
|
Pharmacoeconomics
|
2010
|
2.19
|
|
10
|
Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement.
|
J Comp Eff Res
|
2012
|
1.91
|
|
11
|
Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.
|
Health Policy
|
2010
|
1.83
|
|
12
|
An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
|
Thromb Haemost
|
2008
|
1.76
|
|
13
|
Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics.
|
Med Decis Making
|
2013
|
1.70
|
|
14
|
Design, implementation, and first-year outcomes of a value-based drug formulary.
|
J Manag Care Spec Pharm
|
2015
|
1.67
|
|
15
|
A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke.
|
Ann Emerg Med
|
2012
|
1.58
|
|
16
|
Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.
|
J Gastroenterol Hepatol
|
2007
|
1.58
|
|
17
|
A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics.
|
Genet Med
|
2012
|
1.52
|
|
18
|
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.
|
Med Decis Making
|
2010
|
1.45
|
|
19
|
Economic outcome of cardiac CT-based evaluation and standard of care for suspected acute coronary syndrome in the emergency department: a decision analytic model.
|
Acad Radiol
|
2011
|
1.45
|
|
20
|
The timing of elective colectomy in diverticulitis: a decision analysis.
|
J Am Coll Surg
|
2004
|
1.45
|
|
21
|
Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis.
|
Pharmacogenet Genomics
|
2006
|
1.44
|
|
22
|
Optimizing CAD diagnosis in China with CT angiography.
|
J Cardiovasc Comput Tomogr
|
2009
|
1.43
|
|
23
|
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research.
|
Genet Med
|
2012
|
1.39
|
|
24
|
Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support.
|
BMC Bioinformatics
|
2010
|
1.32
|
|
25
|
Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?
|
Genet Med
|
2005
|
1.27
|
|
26
|
Cost effectiveness of pharmacogenomics: a critical and systematic review.
|
Pharmacoeconomics
|
2010
|
1.19
|
|
27
|
The efficacy and safety of sibutramine for weight loss: a systematic review.
|
Arch Intern Med
|
2004
|
1.19
|
|
28
|
A cost-effectiveness analysis of intraoperative cholangiography in the prevention of bile duct injury during laparoscopic cholecystectomy.
|
J Am Coll Surg
|
2003
|
1.18
|
|
29
|
Prioritization in comparative effectiveness research: the CANCERGEN Experience.
|
Med Care
|
2012
|
1.17
|
|
30
|
Return of incidental findings in genomic medicine: measuring what patients value--development of an instrument to measure preferences for information from next-generation testing (IMPRINT).
|
Genet Med
|
2013
|
1.16
|
|
31
|
The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.
|
Value Health
|
2008
|
1.16
|
|
32
|
Estimating the costs of induced abortion in Uganda: a model-based analysis.
|
BMC Public Health
|
2011
|
1.13
|
|
33
|
Economic analyses of human genetics services: a systematic review.
|
Genet Med
|
2005
|
1.10
|
|
34
|
A review of selected patient-generated outcome measures and their application in clinical trials.
|
Value Health
|
2003
|
1.07
|
|
35
|
Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds.
|
Gastrointest Endosc
|
2003
|
1.07
|
|
36
|
Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).
|
Lung Cancer
|
2008
|
1.06
|
|
37
|
Potential cost-effectiveness of universal access to modern contraceptives in Uganda.
|
PLoS One
|
2012
|
0.98
|
|
38
|
Stakeholder perspectives on a risk-benefit framework for genetic testing.
|
Public Health Genomics
|
2010
|
0.98
|
|
39
|
Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use.
|
Am J Infect Control
|
2003
|
0.97
|
|
40
|
The economics of genomic medicine: insights from the IOM Roundtable on Translating Genomic-Based Research for Health.
|
JAMA
|
2013
|
0.97
|
|
41
|
The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007).
|
Contemp Clin Trials
|
2012
|
0.97
|
|
42
|
Managed care in the genomics era: assessing the cost effectiveness of genetic tests.
|
Am J Manag Care
|
2003
|
0.96
|
|
43
|
Expectations, validity, and reality in pharmacogenetics.
|
J Clin Epidemiol
|
2009
|
0.96
|
|
44
|
Navigational bronchoscopy with biopsy versus computed tomography-guided biopsy for the diagnosis of a solitary pulmonary nodule: a cost-consequences analysis.
|
J Bronchology Interv Pulmonol
|
2012
|
0.95
|
|
45
|
Use of maximal sterile barriers during central venous catheter insertion: clinical and economic outcomes.
|
Clin Infect Dis
|
2004
|
0.95
|
|
46
|
An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis.
|
J Gastroenterol Hepatol
|
2009
|
0.95
|
|
47
|
In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose.
|
Pharmacogenet Genomics
|
2005
|
0.95
|
|
48
|
A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications.
|
Drug Metab Rev
|
2008
|
0.93
|
|
49
|
Cost of chronic hepatitis B infection in the United States.
|
J Clin Gastroenterol
|
2004
|
0.93
|
|
50
|
A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B.
|
Pharmacoeconomics
|
2008
|
0.93
|
|
51
|
Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer.
|
Drugs
|
2008
|
0.92
|
|
52
|
Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs.
|
Am J Manag Care
|
2004
|
0.91
|
|
53
|
Health state preference assessment in diabetic peripheral neuropathy.
|
Pharmacoeconomics
|
2002
|
0.91
|
|
54
|
Cytochrome p450 enzyme polymorphism frequency in indigenous and native american populations: a systematic review.
|
Community Genet
|
2008
|
0.91
|
|
55
|
The clinical and economic consequences of screening young men for genital chlamydial infection.
|
Sex Transm Dis
|
2003
|
0.91
|
|
56
|
Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests.
|
Am J Manag Care
|
2006
|
0.90
|
|
57
|
Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis.
|
Chest
|
2011
|
0.90
|
|
58
|
Preference values associated with stage III colon cancer and adjuvant chemotherapy.
|
Qual Life Res
|
2010
|
0.89
|
|
59
|
Health economic evaluation of non-melanoma skin cancer and actinic keratosis.
|
Pharmacoeconomics
|
2004
|
0.88
|
|
60
|
Long-term survival in patients with severe acute respiratory distress syndrome and rescue therapies for refractory hypoxemia*.
|
Crit Care Med
|
2014
|
0.86
|
|
61
|
Systematic review of comparative effectiveness data for oncology orphan drugs.
|
Am J Manag Care
|
2012
|
0.86
|
|
62
|
The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma.
|
Cancer
|
2005
|
0.86
|
|
63
|
Vascular catheter site care: the clinical and economic benefits of chlorhexidine gluconate compared with povidone iodine.
|
Clin Infect Dis
|
2003
|
0.86
|
|
64
|
Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS.
|
Curr Alzheimer Res
|
2012
|
0.85
|
|
65
|
Cost-consequences of ultrafiltration for acute heart failure: a decision model analysis.
|
Circ Cardiovasc Qual Outcomes
|
2009
|
0.85
|
|
66
|
Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process.
|
J Comp Eff Res
|
2012
|
0.84
|
|
67
|
The cost-effectiveness of primary stroke centers for acute stroke care.
|
Stroke
|
2012
|
0.84
|
|
68
|
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
|
Ann Pharmacother
|
2002
|
0.84
|
|
69
|
The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer.
|
Value Health
|
2009
|
0.84
|
|
70
|
Cost comparison of surgery vs organ preservation for laryngeal cancer.
|
Arch Otolaryngol Head Neck Surg
|
2005
|
0.83
|
|
71
|
A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962).
|
J Pediatr Hematol Oncol
|
2002
|
0.82
|
|
72
|
A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia.
|
Cancer Treat Rev
|
2012
|
0.82
|
|
73
|
Pain, demographics, and clinical characteristics in persons who received hospice care in the United States.
|
J Pain Symptom Manage
|
2006
|
0.82
|
|
74
|
Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.
|
J Med Econ
|
2014
|
0.81
|
|
75
|
Paying for personalized care: cancer biomarkers and comparative effectiveness.
|
Mol Oncol
|
2012
|
0.80
|
|
76
|
Using maximal sterile barriers to prevent central venous catheter-related infection: a systematic evidence-based review.
|
Am J Infect Control
|
2004
|
0.80
|
|
77
|
The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment.
|
J Med Econ
|
2010
|
0.80
|
|
78
|
Comparative economic analyses of minimally invasive direct coronary artery bypass surgery.
|
J Thorac Cardiovasc Surg
|
2003
|
0.80
|
|
79
|
Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men.
|
Pharmacogenetics
|
2004
|
0.79
|
|
80
|
Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis.
|
J Cancer Res Clin Oncol
|
2009
|
0.79
|
|
81
|
Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination.
|
J Infect Dis
|
2011
|
0.79
|
|
82
|
Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation.
|
Pharmacogenet Genomics
|
2009
|
0.79
|
|
83
|
Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research.
|
Genet Med
|
2012
|
0.78
|
|
84
|
CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians.
|
Blood
|
2003
|
0.78
|
|
85
|
Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation.
|
Pharmacogenomics
|
2013
|
0.78
|
|
86
|
Stakeholder perspectives on decision-analytic modeling frameworks to assess genetic services policy.
|
Genet Med
|
2012
|
0.77
|
|
87
|
Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
|
J Med Econ
|
2011
|
0.77
|
|
88
|
The validity of dependence as a health outcome measure in Alzheimer's disease.
|
Am J Alzheimers Dis Other Demen
|
2013
|
0.77
|
|
89
|
Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis.
|
J Comp Eff Res
|
2013
|
0.77
|
|
90
|
Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine.
|
Am J Hum Genet
|
2016
|
0.77
|
|
91
|
CDR state transition probabilities in Alzheimer's disease with and without cholinesterase inhibitor intervention in an observational cohort.
|
J Alzheimers Dis
|
2011
|
0.77
|
|
92
|
Evolving research and stakeholder perspectives on pharmacogenomics.
|
JAMA
|
2011
|
0.76
|
|
93
|
Clinical and demographic characteristics help explain variations in pain at the end of life.
|
J Pain Symptom Manage
|
2007
|
0.76
|
|
94
|
A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results.
|
Med Decis Making
|
2003
|
0.75
|
|
95
|
The cost-effectiveness of interleukin-1 genetic testing for periodontal disease.
|
J Periodontol
|
2002
|
0.75
|
|
96
|
Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT).
|
J Manag Care Spec Pharm
|
2015
|
0.75
|